Novartis, Roche make headway with cancer drugs

05/28/2009 | Reuters

Novartis AG and Roche Holding reported that clinical trials of their cancer drugs yielded positive results. A Phase III trial showed that Novartis' Sandostatin LAR cut the risk of disease progression by 67%. During a midstage study, a combination treatment of Roche's Herceptin and trastuzumab-DM1 helped shrink tumors in 25% of women with HER2-positive breast cancer.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA